Expert Interview
Discussing Merus' MCLA-158 in advanced head and neck squamous cell carcinoma with an author of the 2021 AACR-NCI-EORTC presentation
Ticker(s): MRUSInstitution: UCSD
- Chief, Division of Hematology-Oncolog, Associate Director, Translational Science, Moores Cancer Center & co-director of UC San Diego Health's Precision Immunotherapy Clinic at UCSD.
- Leads a laboratory that studies novel cancer treatments, including immunotherapy, with a focus on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers.
- Recent National Institutes of Health (NIH)-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance.
- Authored more than 170 peer-reviewed papers and has been the principal investigator of multiple clinical trials of new drugs for head and neck cancer and other solid tumors.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
